business
Aegerion Pharmaceuticals (NASDAQ:AEGR) is lower after it reported a Q4 loss that was smaller than analysts had expected and set a FY14 sales guidance that straddled estimates. Shares are down 11.48% at $58.73 with a 52-week range of $28.33 – $101.00. In the quarter, the biopharmaceutical company had a non-GAAP loss of $0.14 per share,…
Del Frisco’s Restaurant (NASDAQ:DFRG) reached a record high Wednesday after reporting an improved Q4 year-over-year but fell short of analysts’ expectations. The company also provided fiscal 2014 earnings guidance below Street estimates. Shares are up 0.74% at $24.44, reaching an all-time high of $25.64. The company, which owns and operates Del Frisco’s Double Eagle Steak House,…
Transocean Ltd. (NYSE: RIG) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in RIG indicates that the price change in the extended hours…
Shares in Abercrombie & Fitch (NYSE: ANF) are up almost 8% pre-market after the retailer reported Q4 earnings that topped expectations. The company said adjusted non-GAAP net income was $104.3 million, or $1.34 per diluted share, more than the $1.05 analysts had been expecting, according to Capital IQ. Q4 GAAP net income was $66.1 million,…
Shares of ExamWorks (NYSE: EXAM) jumped to a new all-time high Wednesday, after the provider of independent medical examinations late Tuesday reported a narrowed Q4 net loss that was smaller than expected while revenue topped Street estimates and the company forecast Q1 and 2014 revenue above analysts’ expectations. EXAM was up 17% at $35.76 recently,…
Dyax Corp (NASDAQ:DYAX) shares rose 8.1% to $10.99, their highest price since mid-2004, after positive Phase 1a study results of DX-2930, a treatment for hereditary angioedema attacks. The first-in-human clinical study of DX-2930 met all objectives of assessing safety, tolerability and pharmacokinetics and showed it well tolerated at all dose levels. Pharmacokinetic results demonstrated that…
